PTT 004
Alternative Names: PTT-004Latest Information Update: 16 Jan 2026
At a glance
- Originator Pyrotech Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Pyroptosis modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
- Research Inflammation
Most Recent Events
- 16 Jan 2026 Phase-I clinical trials in Inflammatory bowel diseases (unspecified route) (Pyrotech Therapeutics pipeline; January 2026)
- 16 Jan 2026 Preclinical trials in Inflammatory bowel diseases in China (unspecified route) (Pyrotech Therapeutics pipeline; November 2025)
- 21 Feb 2024 Early research in Inflammation in China (unspecified route), prior to February 2024 (Pyrotech Therapeutics pipeline, February 2024)